Molecular Diagnostics Market to hit $10bn by 2023: Global Market Insights Inc.
March 20, 2017 06:30 ET
|
Global Market Insights, Inc
Ocean View, Delaware, March 20, 2017 (GLOBE NEWSWIRE) -- The trends outlook report “Molecular Diagnostics Market Size By Infectious Disease (Flu, Tuberculosis, Meningitis, RSV Virus, Hepatitis B,...
Elsevier Updates Infectious Diseases Reference Aimed at Controlling and Preventing Neglected and Emerging Worldwide Diseases
February 27, 2017 04:00 ET
|
Elsevier, Inc.
CAMBRIDGE, MA--(Marketwired - February 27, 2017) - Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the publication of an...
Cempra’s Fusidic Acid Achieves Primary Endpoint in Phase 3 Study of ABSSSI
February 24, 2017 07:00 ET
|
Cempra, Inc.
—Fusidic acid met primary endpoint and secondary efficacy endpoints— —Fusidic acid well tolerated in the study— CHAPEL HILL, N.C., Feb. 24, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a...
Assembly Biosciences Announces Successful Completion of ABI-H0731 Phase 1a Trial and Upcoming Conference Presentations
February 16, 2017 07:05 ET
|
Assembly Biosciences, Inc.
INDIANAPOLIS, Feb. 16, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
Great Basin Scientific’s Shiga Toxin Direct Test Clinical Evaluation and Cost Analysis Published in Journal of Clinical Microbiology
February 03, 2017 07:00 ET
|
Great Basin Scientific, Inc.
SALT LAKE CITY, Feb. 03, 2017 (GLOBE NEWSWIRE) -- Great Basin Scientific, Inc. (OTCQB:GBSN), a molecular diagnostics company, today announced the Journal of Clinical Microbiology published results...
Melinta Therapeutics’ New Drug Application for Baxdela Accepted for Filing by US FDA
January 05, 2017 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today the U.S....
Great Basin Scientific Submits 510(k) Application to the FDA for Stool Bacterial Pathogens Panel
December 19, 2016 07:30 ET
|
Great Basin Scientific, Inc.
SALT LAKE CITY, Dec. 19, 2016 (GLOBE NEWSWIRE) -- Great Basin Scientific, Inc. (OTCQB:GBSN), a molecular diagnostics company, announced today the 510(k) submission for the Stool Bacterial Pathogens...
Great Basin Scientific Granted U.S. Patent for PCR Amplification Suppressor
November 29, 2016 07:30 ET
|
Great Basin Scientific, Inc.
SALT LAKE CITY, Nov. 29, 2016 (GLOBE NEWSWIRE) -- Great Basin Scientific, Inc. (OTCQB:GBSN), a molecular diagnostics company, today announced that the United States Patent and Trademark Office...
Great Basin Scientific to Demonstrate its Diagnostics Platform at AMP 2016
November 10, 2016 07:00 ET
|
Great Basin Scientific, Inc.
SALT LAKE CITY, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Great Basin Scientific, Inc. (OTCQB:GBSN), a molecular diagnostics company, will demonstrate its molecular diagnostics platform at the Association...
Great Basin Scientific Completes Clinical Trial for Stool Bacterial Pathogens Panel
November 08, 2016 07:00 ET
|
Great Basin Scientific, Inc.
SALT LAKE CITY, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Great Basin Scientific, Inc. (OTCQB:GBSN), a molecular diagnostics company, announced today the successful completion of the clinical trial of its...